Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent

Status Active, not recruiting

Clinical Trial Summary

This study will investigate the effect of a peripheral acting opioid antagonist (PAMORA) on the disease course of patients with recurrent acute inflammation of the pancreas (acute pancreatitis). The study will be conducted by treating outpatients suffering from recurrent acute pancreatitis with a PAMORA (naldemedine) for 12 months.

Clinical Trial Description

In this study, the effects of a peripheral acting µ-opioid receptor antagonist (PAMORA) on disease recurrence and progression in patients with recurrent acute pancreatitis (RAP) will be investigated. Patients with RAP will be administered 0,2 mg naldemedine orally daily or matching placebo. This medication is defined as the investigational product. Naldemedine is approved by the European Medical Agency for treatment of opioid-induced constipation. This PAMORA have not previously been investigated in patients with pancreatitis. The dose regimes for this study will be according to label. It has previously been shown, in patients with opioid-induced obstipation and healthy subjects, that opioid antagonism incl. PAMORA treatment increases gut motility, relaxes gastrointestinal sphincters, increases the intestinal water content and improves the immune response, without affecting analgesia. The affinity of PAMORAs to the µ-opioid receptors is much stronger than opioid analgesics. Therefore, they as antagonists have the potential to counteract the harmful effects of opioids on the gut mucosa, bacterial translocation and inflammation despite the high levels of exogenous opioids present in patients with pancreatitis. PAMORAs do not cross the blood-brain barrier and consequently do not interfere with analgesia or other central effects of opioids. It is hypothesized that treatment with the PAMORA naldemedine will antagonize the harmful effects of opioids without reducing analgesia in patients with RAP and hence reduce disease severity and improve clinical outcomes. If successful, this study will for the first time document the effects of a targeted pharmacotherapy in RAP with the potential benefit of improved patient outcomes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04966559
Study type	Interventional
Source	Aalborg University Hospital
Contact
Status	Active, not recruiting
Phase	Phase 2/Phase 3
Start date	January 12, 2022
Completion date	June 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03609944` - SpHincterotomy for Acute Recurrent Pancreatitis	N/A
Recruiting	`NCT05572788` - Rectal Indomethacin to Prevent Acute Pancreatitis in EUS-FNA of Pancreatic Cysts	N/A
Completed	`NCT03642769` - Lactated Ringer's Versus Normal Saline for Acute Pancreatitis	N/A
Active, not recruiting	`NCT05095831` - EUS Shear Wave for Solid Pancreatic Lesions.
Completed	`NCT04570852` - Acute Pancreatitis Targets (APT) Study	N/A
Recruiting	`NCT03686618` - Secretin for Acute Pancreatitis	Phase 2
Not yet recruiting	`NCT03740685` - Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis
Not yet recruiting	`NCT04037449` - Transversus Abdominis Plane Block in the Analgesia of Acute Pancreatitis	N/A
Completed	`NCT03342716` - Resolution of Organ Injury in Acute Pancreatitis - RESORP
Not yet recruiting	`NCT03342807` - Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis	Phase 4
Not yet recruiting	`NCT04760847` - Intermittent Fasting for Pancreatitis	N/A
Terminated	`NCT02959112` - Epinephrine Sprayed on the Papilla Versus Sterile Water Sprayed on the Papilla for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography	N/A
Recruiting	`NCT05381428` - Prophylaxis of Post-ERCP Acute Pancreatitis	Phase 3
Active, not recruiting	`NCT05955235` - A Long-term Safety Follow-up Study of SCM-AGH in Patients Who Completed SCM-APT2001 Study
Recruiting	`NCT05160506` - Corticosteroids to Treat Pancreatitis	Phase 2
Not yet recruiting	`NCT03082469` - Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal	Phase 4
Completed	`NCT03672422` - Pediatric Longitudinal Cohort Study of Chronic Pancreatitis
Completed	`NCT00490386` - Helicobacter Pylori and Acute Alcohol Induced Pancreatitis	N/A
Completed	`NCT04188990` - Cost Effectiveness of an Intervention in Hospitalized Patients With Disease-related Malnutrition	N/A
Active, not recruiting	`NCT04743323` - A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease Progression in Acute Pancreatitis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms